Akero’s Fatty Liver Disease Drug Lessens Scarring in Mid-stage Trial
(Reuters) -Akero Therapeutics' speculative drug for a kind of fatty liver illness considerably minimized scarring after almost 2 years in a mid-stage research study, it stated on Monday, as the business targets a prospective multi-billion-dollar market. The business's shares increased 19% to $33.09 in early morning trade and a minimum of one expert stated the drug revealed one of the most advantage in the little research study compared to any other treatment checked in different trials for the illness. The outcomes will have to be verified in a late-stage trial. South San Francisco, California-based Akero was evaluating the drug, efruxifermin, in a mid-stage trial, that registered 128 metabolic dysfunction-associated steatohepatitis (MASH) clients with scarring or fibrosis at seriousness ...